Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders (2016 - 2025)

Northwest Biotherapeutics' Net Income towards Common Stockholders history spans 16 years, with the latest figure at $1.3 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at $1.3 million for Q4 2025, up 104.39% from a year ago — trailing twelve months through Dec 2025 was -$61.5 million (up 27.84% YoY), and the annual figure for FY2025 was -$61.5 million, up 27.84%.
  • Net Income towards Common Stockholders for Q4 2025 was $1.3 million at Northwest Biotherapeutics, up from -$27.2 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $1.3 million in Q4 2025 to a low of -$60.5 million in Q4 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$18.6 million (2024), against an average of -$20.3 million.
  • The sharpest move saw Net Income towards Common Stockholders tumbled 257.01% in 2021, then skyrocketed 104.39% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$60.5 million in 2021, then soared by 53.23% to -$28.3 million in 2022, then skyrocketed by 49.4% to -$14.3 million in 2023, then plummeted by 99.02% to -$28.5 million in 2024, then skyrocketed by 104.39% to $1.3 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at $1.3 million, -$27.2 million, and -$15.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.